Integer Holdings reported solid full-year 2025 results with 8% sales growth and 21% adjusted EPS growth, driven by strong performance in Cardio & Vascular and contributions from acquisitions. The company is maintaining its 2026 outlook midpoint for sales and the high end for adjusted EPS, signaling confidence in continued underlying growth despite some new product headwinds.
Full year sales increased 8% to $1.854 billion.
positiveAdjusted EPS increased 21% year-over-year to $6.40 for the full year.
positiveCardio & Vascular sales increased 17% year-over-year to $1.107 billion, driven by new product ramps and acquisitions.
positiveThe company intends to commence an accelerated share repurchase program of approximately $50 million.
positiveGAAP operating income decreased 1.9% to $55.9 million in Q4 2025 compared to Q4 2024.
attentionGAAP income from continuing operations decreased 15.1% year-over-year to $102.8 million for full year 2025.
negativeGAAP diluted EPS from continuing operations decreased 15.0% year-over-year to $2.89 for full year 2025.
negativeCardiac Rhythm Management & Neuromodulation sales decreased 1.9% to $167 million in Q4 2025, primarily driven by lower demand from select emerging customers.
attentionOther Markets sales decreased 26.9% year-over-year to $78 million for full year 2025, driven by the decline in Portable Medical.
negativeTotal debt increased $195 million to $1.185 billion, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of December 31, 2025.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Cardio & Vascular | N/A | — | — | — | +4.4% |
Cardiac Rhythm Management & Neuromodulation | N/A | — | — | — | -1.9% |
Other Markets | N/A | — | — | — | +5.9% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Integer delivered strong performance in 2025, achieving 8% sales growth, 13% adjusted operating income growth, and a 21% increase in adjusted EPS.
We have tightened the 2026 outlook range around the midpoint of our preliminary outlook provided last October and continue to expect solid underlying growth to be partially offset by select new product headwinds.
We remain focused on our strategy of advancing our customers’ goals through industry-leading engineering and manufacturing.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.